{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:45:33Z","timestamp":1794775533658,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ard.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:15:48Z","timestamp":1738394148000},"page":"620-631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database"],"prefix":"10.1016","volume":"84","author":[{"given":"Qingran","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Garaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Oliver","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Elhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucsandra","family":"Dobrota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petelytska","family":"Liubov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Balbir-Gurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Mohammad Reza","family":"Beigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ingegnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Del","family":"Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Shuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.01.014_bib0001","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.ard.2025.01.014_bib0002","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","article-title":"Geoepidemiology of systemic sclerosis","volume":"9","author":"Ranque","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.ard.2025.01.014_bib0003","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.014_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.ard.2025.01.014_bib0005","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ard.2025.01.014_bib0006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-020-00953-0","article-title":"Understanding fibrosis in systemic sclerosis: novel and emerging treatment approaches","volume":"22","author":"Yin","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.ard.2025.01.014_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001694","article-title":"All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019","volume":"7","author":"Bournia","year":"2021","journal-title":"RMD Open"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.01.014_bib0008","doi-asserted-by":"crossref","first-page":"154S","DOI":"10.1136\/annrheumdis-2023-eular.1383","article-title":"OP0234\u20052023 update of EULAR recommendations for the treatment of systemic sclerosis","volume":"82","author":"Galdo","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.01.014_bib0009","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"25","key":"10.1016\/j.ard.2025.01.014_bib0010","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ard.2025.01.014_bib0011","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ard.2025.01.014_bib0012","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ard.2025.01.014_bib0013","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.01.014_bib0014","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.01.014_bib0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chest.2022.09.044","article-title":"Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European Scleroderma Trials and Research","volume":"163","author":"Hoffmann-Vold","year":"2023","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ard.2025.01.014_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.ard.2025.01.014_bib0017","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2025.01.014_bib0018","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.01.014_bib0019","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7624","key":"10.1016\/j.ard.2025.01.014_bib0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ard.2025.01.014_bib0021","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.01.014_bib0022","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.01.014_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.01.014_bib0024","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.01.014_bib0025","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ard.2025.01.014_bib0026","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal clinically important differences for the modified Rodnan Skin Score: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.ard.2025.01.014_bib0027","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2021-221307","article-title":"EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology","volume":"81","author":"Courvoisier","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.ard.2025.01.014_bib0028","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.ard.2025.01.014_bib0029","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"llanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.ard.2025.01.014_bib0030","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2025.01.014_bib0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.ard.2025.01.014_bib0032","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.01.014_bib0033","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.42491","article-title":"A Composite serum biomarker index for the diagnosis of systemic sclerosis-associated interstitial lung disease: a multicenter, observational cohort study","volume":"75","author":"Jee","year":"2023","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725000688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725000688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:33:37Z","timestamp":1762086817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0003496725000688"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.014","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}